Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Implantable venous access port infections are mainly due to coagulase negative staphylococci and may be managed by antibiotic lock therapy with retention of the port. Most of the time a vancomycin lock is used. Experimental data show that vancomycin may be poorly effective in eradicating the staphylococcal biofilm in the port. Another disadvantage of Vancomycin-containing lock solution is the occurrence of resistant organisms and the risk of catheter occlusion. Ethanol-containing lock solution is highly effective in vitro and does not expose to the risk of emergence resistance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus

NCT00175370

Staphylococcal Infections

COMPLETED NA

Optimization of Therapeutic Drug Monitoring of Vancomycin in Pediatric Patients With an Implanted Port Catheter

NCT03720132

TERMINATED NA

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

NCT00288418

Bacterial Infections

COMPLETED PHASE3

Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease

NCT00413738

Infection

COMPLETED PHASE3

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

NCT01191840

Bacteremia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type of study: multi-center, randomized, double-blind, parallel-group, controlled clinical trial.

Number of centers: 9 French centers in Auvergne and Rhône-Alpes regions

Medical product Ethanol 40% + Enoxaparine 400UI/ml Versus Vancomycin 5 mg/ml + Héparine 2500UI/ml

Patients

Patients eligible for inclusion will be randomized to one of the two groups:

* Experimental group: 90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
* Control group: 90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study.
* For each group, in case of bacteraemia, the lock therapy is associated with a systemic antibiotic therapy using another venous line and optimized by a specialist in infectious diseases.

Study Performance

Patients will be assessed at baseline D0, 3 days (D3), 10 days (D10), 14 weeks (W14) after D0 as follows:

Visit 1 (D0 - baseline):

* Signature of an informed consent form.
* Demographic and clinical characteristics (sex, age, disease associated with implantable venous access port, implantable venous access port infection data, bacteraemia data)

Days 1 to 10

* Injection of ethanol or vancomycin lock solution in implantable venous access port
* Ethanolemia 30 minutes after injection, on first day
* Side effects evaluation

Visit 2 (D3) and Visit 3 (D10)

* Side effects evaluation
* Blood culture
* Bacteraemia data (antibiotic therapy modification)

Phone contact each week from week 2 to week 13

End Visit (W14)

* Side effects evaluation
* Blood culture
* Bacteraemia data (antibiotic therapy modification)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lock Solution Catheter Related Blood Stream Infections Central Venous Catheter Infection Intravenous Drug Delivery Systems Coagulase-negative Staphylococci Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.

Group Type EXPERIMENTAL

Ethanol 40% + Enoxaparine 400UI/ml

Intervention Type DRUG

control group

90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study

Group Type OTHER

Vancomycine 5 mg/ml + Héparine 2500UI/ml

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ethanol 40% + Enoxaparine 400UI/ml

Intervention Type DRUG

Vancomycine 5 mg/ml + Héparine 2500UI/ml

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman from 18 years old
* With probable or definite implantable venous access port infection
* With or without bacteraemia
* Infection due to coagulase-negative staphylococci (except for lugdunensis Staphylococci)
* Blood culture results available within 48 hours before inclusion
* With health insurance

Exclusion Criteria

* Pregnant or breastfeeding woman
* Allergy to ethanol
* Patient with prosthetic cardiac valve
* Necessity of venous access port withdrawal
* Prior infection on the same venous access port
* Patients under supervision or (legal) guardianship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No